BioRad Laboratories, Inc.
BIO
is slated to report first-quarter fiscal 2021 results on Apr 29, after the closing bell.
In the last-reported quarter, the company’s earnings per share (EPS) of $4.01 surpassed the Zacks Consensus Estimate by 29.4%. Moreover, earnings surpassed the consensus estimate in the last four quarters. The trailing four-quarter average surprise is 37.95%.
Let’s see how things are shaping up prior to the announcement.
Factors at Play
Life Science
Through the pandemic, Bio-Rad has witnessed a pronounced change in product demand across the company’s portfolio, including major shift toward COVID-19 testing and research-related products.
With the pandemic situation more or less remaining unchanged through the months of the first quarter, BioRad is again expected to have maintained strength in its Life Science segment in the first quarter. Robust sales of Bio-Rad’s core Polymerase Chain Reaction (PCR) and Droplet Digital PCR products (dPCR), and Process Media are likely to have maintained momentum in the first quarter as well, similar to the past few months. These factors are expected to have made significant contributions to the top line.
During the fourth-quarter earnings call, BioRad confirmed the receipt of FDA Emergency Use Authorization (EUA) for COVID qPCR assay kit. We expect this multiplex test to have witnessed full-quarter effect of solid customer adoption amid the pandemic. In addition, BioRad confirmed the receipt of EUA approval from the FDA for COVID FluA and FluB qPCR syndromic multiplex test. Considering the current scenario, we believe these products are likely to have registered strong customer adoptions in the to-be-reported quarter, thus adding to the top line.
BioRad Laboratories, Inc. Price and EPS Surprise
Clinical Diagnostics
In the last-reported quarter, BioRad’s Clinical Diagnostics arm put up a dismal performance impacted by lower demand for routine testing and elective surgeries resulting from the pandemic. With the health situation remaining more or less unchanged, we expect the Clinical Diagnostics segment to have experienced weakness across all product lines due to reduced demand from lower non-critical hospital and clinic visits.
Estimate Picture
For first-quarter fiscal 2021, the Zacks Consensus Estimate for totalrevenues of $661 million implies growth of 15.6% from the prior-year reported figure.
The consensus estimate for earnings per share is pegged at $2.50, indicating an improvement of 30.9% from the prior-year reported figure.
What Our Model Suggests
Our proven model does not conclusively predict earnings beat for BioRad this time around. The combination of a positive
Earnings ESP
and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
Earnings ESP:
BioRad has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our
Earnings ESP Filter.
Zacks Rank:
The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.
Elanco Animal Health Incorporated
ELAN
currently has a Zacks Rank #1 and an Earnings ESP of +1.90%. You can see
the complete list of today’s Zacks #1 Rank stocks here.
HCA Healthcare, Inc.
HCA
has an Earnings ESP of +8.91% and a Zacks Rank of 2, at present.
Avenue Therapeutics, Inc.
ATXI
has an Earnings ESP of +16.67% and a Zacks Rank of 2, at present.
Zacks’ Top Picks to Cash in on Artificial Intelligence
In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create “the world’s first trillionaires.” Zacks’ urgent special report reveals 3 AI picks investors need to know about today.
See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report